The USC/Norris Comprehensive Cancer Center began participating in the research activities of the Southwest Oncology Group (SWOG) in 1987 and became a newly funded member institution in 1992. Our participation over the past five years has been characterized by steadily increasing administrative and scientific contributions (consistently ranking in the 2nd-to-3rd quartile among SWOG institutions) and patient accrual (current ranking, 3rd quartile). This has been achieved through the strong support of our Cancer Center which organized and developed several disease-based clinical research programs, provided essential core support for protocol administration, data management, quality assurance monitoring and investigational pharmacy, and implemented an NCI-approved (and grant supplemented) plan to augment the accrual of women and minorities to both intramural and SWOG clinical trials. The disease-based orientation of our Center has allowed SWOG protocols to have a high priority in our Gastrointestinal (GI), Genitourinary (GU), Breast, Hematology/Retroviral and Experimental Therapeutics programs leading to the steady growth in our SWOG patient accrual. In turn, SWOG has been the vehicle through which a growing number of our faculty have been able to bring Center-supported pilot studies and translational research efforts to a national cooperative group. Examples of these latter interactions include our GI Program (members serve as Vice- Chairman SWOG GI Committee, coordinate several SWOG GI protocols and serve as PI of two SWOG U01 grants), GU Program (Program leader serves as principal coordinator of national high-priority neoadjuvant MVAC bladder trial, members participate in funded UCOP and support our designation as a major PCPT study site) and Experimental Therapeutics Program (two highly promising regimens have been adopted into group-wide protocols, SWOG 9509 and 8835). The mutual benefit of this interaction is further reflected by the fact that 15 newly recruited USC faculty in eight different departments or divisions (GI Surgery, Surgical Oncology, Urology, Radiation Oncology, Pathology, Pulmonary Medicine, Hematology, and Oncology) have become SWOG members over the past three years. Despite major challenges from managed care in Southern California and diminished support for public health care facilities such as the USC/Los Angeles County Hospital over the past several years, our SWOG activities have grown. We therefore renew our commitment to SWOG research activities with confidence and the expectation of continued growth in patient and minority accrual, CGOP affiliates and administrative/ scientific leadership in several disease-focused areas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA058882-07
Application #
2856335
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1993-02-01
Project End
2002-12-31
Budget Start
1999-01-01
Budget End
1999-12-31
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Bohanes, Pierre; Rankin, Cathryn J; Blanke, Charles D et al. (2015) Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res 21:1583-90
Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2015) Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol 10:110-5
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 134 publications